Vigonvita Life Sciences Co., Ltd. filed its Monthly Return for March 2026, confirming stable share capital structure and full compliance with Hong Kong listing requirements.

Key highlights

1. Authorised / registered share capital • Total authorised share capital remained unchanged at 167.60 million shares (par value RMB 1 each), equivalent to RMB 167.60 million. – H-share tranche: 66.68 million shares. – Unlisted domestic tranche: 100.92 million shares.

2. Issued share capital and treasury shares • Issued H shares stood at 66.68 million, with no treasury shares held. • Issued unlisted domestic shares stayed at 100.92 million. • No movements—issuance, cancellation, or buy-backs—were recorded during the month.

3. Public float position • The company confirmed adherence to the Main Board’s minimum 25% public float threshold for its H shares as at 31 March 2026.

4. Capital-raising instruments • The filing states there were no outstanding or newly issued share options, warrants, convertible securities, or other equity-linked instruments.

5. Board confirmation • The board secretary affirmed that any share-related activities comply with all applicable laws, listing rules, and regulatory requirements.

With no changes in issued capital or treasury activity during March, Vigonvita Life Sciences maintains a consistent capital base while meeting all exchange obligations.